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Abstract
The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids (CEF) of EFSA was
requested to deliver a scientiﬁc opinion on the implications for human health of the ﬂavouring
substance 3-(1-((3,5-dimethylisoxazol-4-yl)methyl)-1H-pyrazol-4-yl)-1-(3-hydroxybenzyl)imidazolidine-
2,4-dione [FL-no: 16.127], in the Flavouring Group Evaluation 400 (FGE.400), according to Regulation
(EC) No 1331/2008 of the European Parliament and of the Council. The substance has not been
reported to occur in natural source materials of botanical or animal origin. It is intended to be used as
a ﬂavour modiﬁer in speciﬁc categories of food. There is no safety concern with respect to
genotoxicity. A 90-day dietary administration study in rats showed no adverse effects for doses up to
100 mg/kg body weight (bw) per day, providing an adequate margin of safety. Developmental toxicity
was not observed in a study with rats at dose levels up to 1,000 mg/kg bw per day. The
Panel concluded that [FL-no: 16.127] is not expected to be of safety concern at the estimated levels of
intake. This conclusion applies only to the use of the substance as a ﬂavour modiﬁer and when used at
levels up to those speciﬁed for various foods in different food categories.
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Summary
Following a request from the European Commission (EC), the European Food Safety Authority
(EFSA) Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids (CEF Panel) was
asked to deliver a scientiﬁc opinion on the implications for human health of a chemically deﬁned
ﬂavouring substance used in or on foodstuffs in the Member States. In particular, EFSA was requested
to evaluate 3-(1-((3,5-dimethylisoxazol-4-yl)methyl)-1H-pyrazol-4-yl)-1-(3-hydroxybenzyl)imidazolidine-
2,4-dione, in the Flavouring Group Evaluation 400 (FGE.400) using the Procedure as referred to in
Regulation (EC) No 1334/2008 of the European Parliament and of the Council.
The ﬂavouring substance 3-(1-((3,5-dimethylisoxazol-4-yl)methyl)-1H-pyrazol-4-yl)-1-(3-hydroxybenzyl)
imidazolidine-2,4-dione [FL-no: 16.127], contains a number of structural elements common to different
chemical groups listed in Annex I to Commission Regulation (EC) No 1565/20001 but cannot be
adequately covered by any existing FGE. Consequently, the Panel decided to assess this substance on
its own.
3-(1-((3,5-Dimethylisoxazol-4-yl)methyl)-1H-pyrazol-4-yl)-1-(3-hydroxybenzyl)imidazolidine-2,4-dione
has not been reported to occur in natural source materials of botanical or animal origin. There are no
reports of its detection in processed foods.
Speciﬁcations
Speciﬁcations including complete purity criteria and identity for the material of commerce have
been provided and considered adequate. The candidate substance does not possess chiral centres or
geometrical isomers.
The information provided on the manufacturing process, the composition and the stability of the
ﬂavouring substance was considered sufﬁcient.
Use and exposure
3-(1-((3,5-Dimethylisoxazol-4-yl)methyl)-1H-pyrazol-4-yl)-1-(3-hydroxybenzyl)imidazolidine-2,4-dione
is intended to be used as a modiﬁer2 of the bitter taste of speciﬁc food categories.
The cumulative dietary exposure to the candidate substance has been estimated using the added
portions exposure technique (APET). It is calculated to be 850 lg/capita per day (14 lg/kg body
weight (bw) per day for a 60-kg adult) and 536 lg/capita per day (36 lg/kg bw per day for a 15-kg
3-year-old child).
Although the substance is not intended to be used in food categories speciﬁcally intended for
infants and young children, these could still be exposed through consumption of foods from the
general food categories, which may contain the substance. However, at present, there is no generally
accepted methodology to estimate exposure in these age groups resulting from consumption of foods
from the general categories.
The highest acute intake of the candidate substance results from the consumption of non-alcoholic
beverages containing 8 mg/kg of the candidate substance consumed by a 15-kg 3-year-old child. This
results an intake of 4.5 mg/capita per day (or 300 lg/kg bw per day for a 15-kg 3-year-old child).
Absorption, distribution, metabolism and elimination
The absorption, distribution, metabolism and elimination (ADME) studies available for [FL-no:
16.127] indicate that the bioavailability of the compound is 2–4% of the orally administered dose.
However, the information on the mass balance and metabolic fate of the substance in vivo is
incomplete. Therefore, the extent of absorption cannot be estimated from the available data. In blood,
mainly some conjugates and a minor amount of oxidised metabolites were observed. In vitro studies
with microsomes (rat and human) indicate very limited phase I metabolism of the candidate
substance.
Genotoxicity
No structural alerts have been identiﬁed for [FL-no: 16.127]. In tests carried out in vitro and
in vivo, [FL-no: 16.127] showed no potential to cause gene mutations, structural chromosomal
1 Commission Regulation No 1565/2000 of 18 July 2000 laying down the measures necessary for the adoption of an evaluation
programme in application of Regulation No 2232/96 of the European Parliament and of the Council. Ofﬁcial Journal of the
European Union, L 180, p. 8–16.
2 Regulation No 1334/2008 of the European Parliament and of the Council of 16 December 2008 on ﬂavourings and certain food
ingredients with ﬂavouring properties for use in and on foods and amending Council Regulation No 1601/91, Regulations
No 2232/96 and No 110/2008 and Directive 2000/13/EC. Ofﬁcial Journal of the European Union, L 354, p. 34–50.
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aberrations or numerical chromosomal aberrations. The Panel concluded that there is no cause for
concern with respect to genotoxicity.
Systemic toxicity
A 90-day systemic toxicity study in the rat has been performed. Dietary administration of [FL-no:
16.127] to CD rats for 13 weeks at doses up to 100 mg/kg bw per day was well tolerated, with the
only effect being a slight increase in motor activity which was observed only in the high-dose males.
Based on the ﬁndings in this study, the no-observed-effect-level (NOEL) was considered to be 30 mg/kg
bw per day for males and 100 mg/kg bw per day for females, and the no-observed-adverse-effect-
level (NOAEL) was 100 mg/kg per day in both sexes.
Developmental toxicity
In a developmental toxicity study, rats were administered oral doses of 125–1,000 mg/kg bw per
day of the candidate substance. There were no differences between the treated and control groups.
Therefore, there is no concern for developmental toxicity of [FL-no: 16.127] in rats at dose levels up to
1,000 mg/kg bw per day.
Safety assessment for acute exposure
Estimates of maximum acute dietary exposure indicate that this would be about 0.3 mg/kg bw for
a 3-year-old child. Doses of 2,000 mg/kg bw and probably higher are well tolerated in mice without
adverse effects. No signiﬁcant changes in body weight or apparent signs of toxicity were observed in
mice administered this dose during the 48-h study period in an in vivo micronucleus assay. This results
in a margin of exposure of more than 6 9 103 for children and 1.7 9 104 for adults.
Safety assessment for long-term exposure
The safety of long-term exposure has been evaluated according to the Procedure for the evaluation
of chemically deﬁned ﬂavouring substances.
For the substance [FL-no: 16.127], there is no concern in relation to genotoxicity and it can be
evaluated through the Procedure.
There is no clear structural/metabolic similarity of the candidate substance to ﬂavouring substances
in an existing FGE and accordingly the candidate substance [FL-no: 16.127] has been individually
evaluated according to the EFSA Guidance document.
Based on its chemical structure, the substance has been assigned to Cramer class III. The results
of studies on metabolism and pharmacokinetics do not allow the conclusion that its metabolites are
innocuous. Accordingly, the candidate substance is evaluated via the B-side of the Procedure scheme.
Based on the comparison of APET with the Cramer class III threshold, a 90-day study and a
developmental toxicity study were required and carried out for this substance.
Overall, the Panel concluded that using the NOAEL obtained from a 90-day dietary study in rats,
there is no safety concern for [FL-no: 16.127], when used as a ﬂavour modiﬁer at the estimated level
of dietary exposure calculated using the APET approach and based on the use levels in food as
speciﬁed in Appendix C. An adequate margin of safety of over 7,000 for adults and 2,000 for 3-year-old
children has been estimated.
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1. Introduction
1.1. Background and Terms of Reference as provided by the requestor
The use of ﬂavourings is regulated under Regulation (EC) No 1334/20083 of the European
Parliament and Council of 16 December 2008 on ﬂavourings and certain food ingredients with
ﬂavouring properties for use in and on foods. On the basis of Article 9(a) of this Regulation, an
evaluation and approval are required for ﬂavouring substances.
The Union List of ﬂavourings and source materials was established by Commission Implementing
Regulation (EC) No 872/20124. Regulation (EC) No 1331/2008 shall apply for the evaluation and
approval of ﬂavouring substances which are not covered by the evaluation programme provided for in
Article 4 of Regulation (EC) No 2232/965.
The Commission has received an application for an authorisation of a new ﬂavouring substance
3-(1-((3,5-dimethylisoxazol-4-yl)methyl)-1H-pyrazol-4-yl)-1-(3-hydroxybenzyl)imidazolidine-2,4-dione.
In order for the Commission to be able to consider its inclusion in the Union list of ﬂavourings and
source materials, the European Food Safety Authority (EFSA) should carry out a safety assessment of
this substance.
1.1.1. Terms of Reference as provided by the European Commission
The European Commission (EC) requests EFSA to carry out a safety assessment on 3-(1-((3,
5-dimethylisoxazol-4-yl)methyl)-1H-pyrazol-4-yl)-1-(3-hydroxybenzyl)imidazolidine-2,4-dione [FL-no:
16.127] as a ﬂavouring substance in accordance with Regulation (EC) No 1331/2008 establishing a
common authorisation procedure for food additives, food enzymes and food ﬂavourings.
1.2. Interpretation of the Terms of Reference
The present scientiﬁc opinion Flavouring Group Evaluation 400 (FGE.400) covers the safety assessment
of 3-(1-((3,5-dimethylisoxazol-4-yl)methyl)-1H-pyrazol-4-yl)-1-(3-hydroxybenzyl)-imidazolidine-2,4-dione
[FL-no: 16.127]. This substance will be evaluated as a ﬂavour modiﬁer [cf. Regulation (EC) No: 1334/2008].
2. Assessment
2.1. Identiﬁcation of the substance
The name of the ﬂavouring substance is 3-(1-((3,5-dimethylisoxazol-4-yl)methyl)-1H-pyrazol-4-yl)-1-
(3-hydroxybenzyl)imidazolidine-2,4-dione, Flavour Information System (FLAVIS)-number: [FL-no:
16.127], Chemical Abstract Service (CAS) no: 1119831-25-2.
2.2. Existing authorisations and evaluations
The substance [FL-no: 16.127] has been evaluated by the Joint FAO/WHO Expert Committee on
Food Additives (JECFA) to be of no safety concern (June, 2012 – JECFA No 2161) and has a Flavor and
Extract Manufacturers Association (FEMA) GRAS status (FEMA 4725).
2.3. Manufacturing process
2.3.1. Source material
The candidate substance is chemically synthesised. Information on the source materials (starting
chemicals, intermediates, reagents and process solvents) has been provided. This information was
classiﬁed as conﬁdential by the applicant, but is available to EFSA.
3 Regulation (EC) No 1334/2008 of the European Parliament and of the Council of 16 December 2008 on ﬂavourings and certain
food ingredients with ﬂavouring properties for use in and on foods and amending Council Regulation (EEC) No 1601/91,
Regulations (EC) No 2232/96 and (EC) No 110/2008 and Directive 2000/13/EC. Ofﬁcial Journal of the European Communities.
L 354, 31.12.2008, p. 34–50.
4 EC (European Commission), 2012. Commission implementing Regulation (EU) No 872/2012 of 1 October 2012 adopting the list
of ﬂavouring substances provided for by Regulation (EC) No 2232/96 of the European Parliament and of the Council,
introducing it in Annex I to Regulation (EC) No 1334/2008 of the European Parliament and of the Council and repealing
Commission Regulation (EC) No 1565/2000 and Commission Decision 1999/217/EC. Ofﬁcial Journal of the European
Communities. OJ L 267, 2.10.2012, p. 1–167.
5 OJ L 299, 23.11.1996, p. 1.
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2.3.2. Genetically modiﬁed organism
Not applicable.
2.3.3. Production process
The principles of the synthesis have been provided. Information on the production process was
classiﬁed as conﬁdential by the applicant, but is available to EFSA.
Considering the starting materials and the employed reaction and puriﬁcation steps, the
Panel concluded that the manufacturing process would not raise safety concern.
2.4. Speciﬁcations
The speciﬁcations of the candidate ﬂavouring substance are detailed in Table 1.
2.4.1. Chemical name
IUPAC: 3-(1-((3,5-Dimethylisoxazol-4-yl)methyl)-1H-pyrazol-4-yl)-1-(3-hydroxybenzyl)imidazolidine-
2,4-dione.
CAS: 2,4-Imidazolidinedione, 3-[1-[(3,5-dimethyl-4-isoxazolyl)methyl]-1H-pyrazol-4-yl]-1-[(3-hydroxy
phenyl) methyl].
2.4.2. Identiﬁcation numbers
CAS no: 1119831-25-2
FLAVIS-no: [FL-no: 16.127]
FEMA GRAS: 4725
2.4.3. Chemical and structural formula, molecular weight
Chemical formula: C19H19N5O4
Molecular weight: 381.38 Da
2.4.4. Physical form/odour
White to cream-coloured odourless powder.
2.4.5. Solubility data
The following maximum concentrations were obtained at room temperature:
Water (pH 7.1; phosphate buffer): 88 mg/l.
Ethanol: > 9,500 mg/l.
Dimethyl sulfoxide: > 38,000 mg/l.
The Panel calculated a log Po/w of 0.92.
2.4.6. Identity tests
Nuclear magnetic resonance (NMR), ultraviolet (UV), infrared spectroscopy (IR) and high-
performance liquid chromatography (HPLC) data have been provided.
2.4.7. Purity/minimum assay value
Minimum assay value: 99.0% by HPLC/UV.
Ethanol and ethyl acetate: ≤ 0.2% by gas chromatography (GC) and NMR.
2.4.8. Impurities
No impurities were detected by HPLC (limit of detection: 0.1%). Analytical data were provided on
the levels of ethanol (0.15–0.17% by weight) and ethyl acetate (0.15% by weight) in three
commercial batches. No other impurities (byproducts or intermediates, reagents and solvents used in
the production process) were observed.
2.4.9. Physical parameters
Melting point: 145–150°C at 986 hPa. According to the industry, the substance [FL-no: 16.127] exhibits
crystal polymorphism which can explain the rather wide melting point range (Flavour Industry, 2013).
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2.4.10. Conﬁguration
The candidate substance does not possess any asymmetric centres. No geometric isomers are
possible. No positional isomers were observed by NMR spectroscopy.
2.4.11. Stability and decomposition products
2.4.11.1. Stability under aqueous conditions
The hydrolytic stability of [FL-no: 16.127] was evaluated in aqueous buffer solutions at various time
points over a range of pH values and temperatures by means of liquid chromatography/mass
spectrometry (LC/MS). At room temperature, [FL-no: 16.127] was stable for at least 24 h at pH 2.8,
5.0 and 7.1 with recoveries ranging from 104% to 106%. At 60°C, [FL-no: 16.127] was stable for at
least 28 days at pH 6.0 (113% recovery), whereas at pH 7.1, ~ 81% remained after 28 days. At
100°C, [FL-no: 16.127] was stable for at least 24 h at pH 2.8 and 5.0, whereas at pH 7.1, 68% of
[FL-no: 16.127] remained after 24 h.
Upon heating of [FL-no: 16.127] in phosphate buffer (pH 7.1) at 100°C for 24 h, a number of
degradation products were formed (Figure 1).
The stability of [FL-no: 16.127] in aqueous products was also evaluated in typically heat-processed
beverages similar to those intended to be marketed. The studies included, for example, the simulation
of coffee beverages manufacturing by applying UHT aseptic processing parameters (140°C for 30 s) or
involving packaging in gusseted retort pouches and processing in steam/air overpressure to obtain
commercial sterility. In all cases, the analytical results demonstrated no signiﬁcant degradation of
[FL-no: 16.127].
In summary, it was shown that in aqueous solutions the pH is the critical factor for the stability of
[FL-no: 16.127]. The ﬂavouring substance exhibits much higher stability in a pH range from 2.8 to 6.0
compared to neutral or basic conditions. According to the applicant, it is recommended that [FL-no:
16.127] should be used in aqueous products at a pH below 6.0 or that the duration of the heating
used for processing should be controlled to ensure its stability. The Panel noted that based on the
stability tests conducted at 60°C and 100°C, no signiﬁcant degradation in beverages stored for several
months at room temperature is to be expected.
2.4.11.2. Stability under dry conditions
Investigation of the thermal stability of [FL-no: 16.127] as a dry powder via LC/MS demonstrated
that the ﬂavouring substance was found to be stable at 100°C for at least 24 h (108% recovery); 76%
of the substance [FL-no: 16.127] remained after 4 h at 200°C, whereas 60% of the material remained
unchanged after 24 h at this temperature.
Figure 1: Proposed structures of degradation products upon heating of [FL-no: 16.127] (synonymous
to S6821) in phosphate buffer (pH 7.1) at 100°C for 24 h
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As a follow-up to the studies at 200°C, the dry powder stability was evaluated at intermediate
temperatures, 150°C and 175°C after heating for 0, 1, 5 and 24 h. In this study, 100% of the
compound remained intact after 24 h at 150°C and 95% remained after 24 h at 175°C.
When [FL-no: 16.127] was heated as a dry powder, the following oxidation product was identiﬁed
(Figure 2):
2.4.11.3. Stability in model foods
When evaluated in key product prototypes, [FL-no: 16.127] was found to be stable in model cakes
(95–105% recovery), cookies (103–109% recovery) and hard candies (111–119% recovery) under
typical processing conditions (204°C for 8 min, 177°C for 30 min and 149°C for 30 min, respectively).
The concentrations of the thermal oxidation product DP395 and of the hydrolytic degradation product
DP192 were below the respective limits of detection (LOD) in all products (LODs for DP395 are
0.05 mg/kg in cakes, 0.12 mg/kg in cookies and 0.13 mg/kg in candies; LODs for DP192 are 0.29 mg/kg
in cakes and cookies, and 0.02 mg/kg in candies). The hydrolysis product DP399 was formed at low
levels in cakes and cookies (0.14 mg/kg in cakes and 0.58 mg/kg in cookies). The substance DP399
could not be detected in candies (LOD = 0.15 mg/kg).
2.4.11.4. Interaction with food components
Trials in which the stability of [FL-no: 16.127] was assessed in different aqueous media as would be
encountered in food and beverage applications did not indicate any chemical interaction with other
food components.
2.4.12. Particle size
As [FL-no: 16.127] is produced as a solid powder, the particle size and particle size distribution
have been measured.6 The particle size and particle size distribution measured by light scattering are
such that the D(50) = 25 lm and D(90) = 69 lm.
To determine whether the particle falls under the deﬁnition of nanomaterial, the speciﬁc surface
area has been measured through the Brunauer–Emmett–Teller (BET) isotherm according to a method
described by Brunauer et al. (1938), using an external laboratory.
The ﬁndings were:
Speciﬁc surface area (single-point determination): 0.24 m2/g; speciﬁc surface area: 0.25 m2/g
Based on the proposed deﬁnition of a nanomaterial by the EC,7 it is concluded that the candidate
substance is not a nanomaterial.
2.4.12.1. Conclusion on speciﬁcations and stability
The Panel considered the compositional data and the information on the stability of the ﬂavouring
substance as sufﬁcient.
Figure 2: Structure of the major oxidation product DP395 formed upon heating of [FL-no: 16.127] as
dry powder
6 As required by Article 10(c) of Commission Regulation (EU) No 234/2011 of 10 March 2011 implementing Regulation (EC)
No 1331/2008 of the European Parliament and of the Council establishing a common authorisation procedure for food
additives, food enzymes and food ﬂavourings.
7 Commission Recommendation 2011/696/EU of 18 October 2011 on the deﬁnition of nanomaterials. Published in the Ofﬁcial
Journal of the European Union L257/38–40 on 20.10.2010 (http://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:
32011H0696&from=EN).
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2.5. Structural/metabolic similarity to substances in an existing FGE
(Appendix B)
The candidate substance [FL-no: 16.127] has a number of structural elements common to different
chemical groups listed in Annex I to Commission Regulation (EC) No 1565/20008. However, the
structure of [FL-no: 16.127] does not allow its integration into one of the existing FGEs. Studies on its
metabolism suggest that it is not transformed into substances that ﬁt into existing FGEs; however, the
information on the metabolic fate of the substance is incomplete.
As none of the already evaluated substances has been identiﬁed with sufﬁcient structural similarity
to the candidate substance, the evaluation of this FGE follows the procedure for individual substances,
described in the EFSA guidelines (EFSA CEF Panel, 2010) (See Appendix A).
2.6. Exposure assessment (Appendix C)
All data necessary for the calculation of normal and maximum occurrence levels for reﬁned
subcategories of foods and beverages are reported in Appendix C.
2.6.1. Natural occurrence
The candidate substance 3-(1-((3,5-dimethylisoxazol-4-yl)methyl)-1H-pyrazol-4-yl)-1-(3-hydroxybenzyl)
imidazolidine-2,4-dione is a synthetic substance. It has not been reported to have been identiﬁed in
natural vegetable or animal source materials. It has not been reported to have been identiﬁed in
unprocessed or processed food.
2.6.2. Non-food sources of exposure
The candidate substance could conceivably be used to modify the bitterness of pharmaceuticals. No
information on this use is presently available. According to the information provided by the applicant,
this is not anticipated.
No information has been provided on possible exposure of the candidate substance from use in
cosmetics and detergents.
Table 1: Speciﬁcation summary of the substances in the Flavouring Group Evaluation 400
FL-no
JECFA
no
EU Register
name
Structural formula
FEMA no
CoE no
CAS no
Phys. form
Mol. formula
Mol. weight
Solubility(a)
Solubility in
ethanol(b)
Others(c)
Boiling
point, °C(d)
Melting
point, °C
ID test
Assay
minimum
Refrac.
index(e)
Spec.
gravity(f)
EFSA
comments
16.127
2161
3-(1-((3,5-
dimethylisoxazol-
4-yl)methyl)-1H-
pyrazol-4-yl)-1-
(3-hydroxybenzyl)
imidazolidine-2,4-
dione
HO
N N
N
N
N
O
O
O
4725
–
1119831-25-2
Odourless,
solid
C19H19N5O4
381.38
Insoluble
Slightly soluble
Soluble
–
145–150°C
IR, UV, NMR,
MS
99%
–
–
FL-no: FLAVIS number; JECFA: The Joint FAO/WHO Expert Committee on Food Additives; EU: European Union; FEMA: Flavor and Extract Manufacturers
Association; CoE: Council of Europe; CAS: Chemical Abstract Service; ID: identity; IR: infrared spectroscopy; MS: mass spectrometry; NMR: nuclear magnetic
resonance; UV: ultraviolet.
(a): Solubility in water, if not otherwise stated.
(b): Solubility in 95% ethanol, if not otherwise stated.
(c): Solubility in dimethyl sulfoxide.
(d): At 1013.25 hPa (1 atm), if not otherwise stated.
(e): At 20°C, if not otherwise stated.
(f): At 25°C, if not otherwise stated.
8 Commission Regulation (EC) No 1565/2000 of 18 July 2000 laying down the measures necessary for the adoption of an
evaluation programme in application of Regulation (EC) No 2232/96. OJ L 180, 19.7.2000, p. 8–16.
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2.6.3. Chronic dietary exposure
The exposure assessment to be used in the Procedure for the safety evaluation of the candidate
substance is the chronic added portions exposure technique (APET) estimate (EFSA CEF Panel, 2010).
The chronic APET has been calculated for adults and children (see Table 2), and these values,
expressed per kg body weight (bw), will be used in the Procedure (see Appendices C and G).
Although the substance is not intended to be used in food categories speciﬁcally intended for
infants and young children, these could still be exposed through consumption of foods from the
general food categories, which may contain the substance. However, at present, there is no generally
accepted methodology to estimate exposure in these age groups resulting from consumption of foods
from the general categories.
2.6.4. Acute dietary exposure
The calculation was based on the maximum use levels and large portion size – i.e. 3 times normal
portion size (see Appendix C).
Although the substance is not intended to be used in food categories speciﬁcally intended for
infants and young children, these could still be exposed through consumption of foods from the
general food categories, which may contain the substance. However, at present, there is no generally
accepted methodology to estimate exposure in these age groups resulting from consumption of foods
from the general categories.
2.6.5. Cumulative dietary exposure
2.6.5.1. Structurally and metabolically related ﬂavouring substances
There are no other ﬂavouring substances structurally and metabolically related to [FL-no: 16.127]
or potentially relevant non-food sources.
Table 2: Chronic dietary exposure estimate
FL-no:
Chronic APET
Added(a)
(mg/kg bw per day)
Other dietary sources(b)
(mg/kg bw per day)
Combined(c)
(mg/kg bw per day)
Use level Normal Average Normal
16.127 Adults(d) 0.014 0 0.014
Children(e) 0.036 0 0.036
APET: added portions exposure technique; bw: body weight.
(a): APET added is calculated on the basis of the amount of ﬂavour added to a speciﬁc food category.
(b): APET other dietary sources is calculated based on the natural occurrence of the ﬂavour in a speciﬁed food category.
(c): APET combined is calculated based on the combined amount of added ﬂavour and naturally occurring ﬂavour in a speciﬁed
food category.
(d): For the adult APET calculation, a 60-kg person is considered representative.
(e): For the child APET calculation, a 3-year-old child with a 15-kg bw is considered representative.
Table 3: Acute dietary exposure estimate
FL-no:
Acute APET
Added(a)
(mg/kg bw per day)
Other dietary sources(b)
(mg/kg bw per day)
Combined(c)
(mg/kg bw per day)
Use level Normal Average Normal
16.127 Adults(d) 0.12 0 0.12
Children(e) 0.30 0 0.30
APET: added portions exposure technique; bw: body weight.
(a): APET added is calculated on the basis of the amount of ﬂavour added to a speciﬁc food category.
(b): APET other dietary sources is calculated based on the natural occurrence of the ﬂavour in a speciﬁed food category.
(c): APET combined is calculated based on the combined amount of added ﬂavour and naturally occurring ﬂavour in a speciﬁed
food category.
(d): For the adult APET calculation, a 60-kg person is considered representative.
(e): For the child APET calculation, a 3-year-old child with a 15 kg bw is considered representative.
Flavouring Group Evaluation 400
www.efsa.europa.eu/efsajournal 12 EFSA Journal 2016;14(7):4334
2.7. Exposure compared to the threshold of toxicological concern (TTC)
By comparison of the APET exposure estimate with the TTCs and TTCs 9 10 (see Table 4), it
follows from the Procedure (see Appendix A) that for the evaluation of the candidate ﬂavouring
substance the results of a 90-day oral toxicity study and a developmental toxicity study are necessary
(see Appendix A). These studies have been submitted by the applicant.
2.8. Absorption, distribution, metabolism and elimination (Appendix D)
The absorption, distribution, metabolism and elimination (ADME) studies available for [FL-no:
16.127] indicate that the bioavailability of the compound is 2–4% of the orally administered dose.
However, the information on the mass balance and metabolic fate of the substance in vivo is
incomplete; therefore, the extent of absorption cannot be estimated from the available data. The
studies reported in Appendix D indicate that the primary metabolites of [FL-no: 16.127] in plasma are
the glucuronide and sulfate conjugates of [FL-no: 16.127]. Only very small amounts of
monohydroxylation products (of the benzyl and isoxazole rings) as well as their corresponding sulfate
conjugates were also observed. The study in rat liver microsomes indicated the formation of one
monohydroxylated metabolite of [FL-no: 16.127] identiﬁed as 3,4-dihydroxybenzyl-[FL-no: 16.127]
(identiﬁed as S6260 in Figure D.1 in Appendix D). Human liver microsomes formed at least four
detectable monohydroxylated metabolites. Two are hydroxylated on the benzyl ring: the 2,5-
dihydroxybenzyl derivative of [FL-no: 16.127] and the 3,4-dihydroxybenzyl derivative of [FL-no:
16.127] (identiﬁed, respectively, as S6262 and S6260 in Figure D.1 in Appendix D).
2.9. Genotoxicity data (Appendix E)
No structural alerts have been identiﬁed for [FL-no: 16.127]. In tests carried out in vitro and
in vivo, [FL-no: 16.127] showed no potential to cause gene mutations, structural chromosomal
aberrations or numerical chromosomal aberrations.
The amine hydrolysis product, S6893 (is the same as DP192), did not induce gene mutations in a
bacterial reverse mutation assay (AMES test; plate incorporation assay only).
The Panel concluded that there is no cause for concern with respect to genotoxicity.
2.10. Toxicity data (Appendix F)
2.10.1. 90-day dietary systemic toxicity study in rats
A 90-day systemic toxicity study in the rat was performed according to the Organisation for
Economic Co-operation and Development ((OECD))-guideline 408 and to good laboratory practice
(GLP) (Huntingdon Life Sciences, 2010e). Dietary administration of [FL-no: 16.127] to CD rats for
13 weeks at doses up to 100 mg/kg bw per day was well tolerated, with the only effect being a slight
increase in motor activity which was observed only in the high-dose males. As the increase in motor
activity was not considered adverse, the Panel considered that the no-observed-adverse-effect-level
(NOAEL) was 100 mg/kg bw per day in both sexes.
2.10.2. Developmental toxicity study in rats
In a developmental toxicity study according to the GLP and OECD testing guideline 414, rats were
administered oral doses of 125–1,000 mg/kg bw per day of the candidate substance. There were no
Table 4: Summary table on calculated chronic APET and threshold of concern
Substance
FL-no:
Structural
class
Threshold of
concern
lg/person
per day
Threshold of
concern x 10
lg/person
per day
Add APET
lg/person
per day
Add APET lg/kg
bw per day
Adult [16.127] III 90 900 850 14
Child [16.127] III 90 900 535 36
APET: added portions exposure technique.
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differences between the treated and control groups. Therefore, there is no concern for developmental
toxicity of [FL-no: 16.127] in rats at dose levels up to 1,000 mg/kg bw per day.
2.11. Safety assessment
2.11.1. Safety assessment for acute exposure
Estimates of maximum acute dietary exposure indicate that this would be about 0.3 mg/kg bw for
a 3-year-old child. Doses of 2,000 mg/kg bw and probably higher are well tolerated in mice without
adverse effects. No signiﬁcant changes in body weight or apparent signs of toxicity were observed in
mice administered this dose during the 48-h study period in an in vivo micronucleus assay. This gives a
margin of exposure of more than 6 9 103 for children and 1.7 9 104 for adults.
2.11.2. Safety assessment for long-term exposure
The safety of long-term exposure will be evaluated according to the Procedure for the evaluation of
chemically deﬁned ﬂavouring substances.
Based on the genotoxicity data available, the Panel concluded that for the candidate substance
[FL-no: 16.127] there is no safety concern with respect to genotoxicity. Consequently, the substance
can be evaluated through the Procedure.
For [FL-no: 16.127], as there is no clear structural/metabolic similarity to other ﬂavouring substances
evaluated in an existing FGE, the Panel decided to assess this substance through the Procedure for the
evaluation of individual ﬂavouring substances (EFSA CEF Panel, 2010) see Appendix A.
2.11.2.1. Procedure steps
Step 1. Decision on structural class
On the basis of its chemical structure, the substance [FL-no: 16.127] is classiﬁed in structure class
III (Cramer et al., 1978).
Step 2. Are there data available to demonstrate that metabolites are to be considered innocuous?
The data available do not show that metabolites can be considered to be innocuous. Therefore,
[FL-no: 16.127] is evaluated through the B-side of the Procedure.
Step B3. Is the dietary exposure below the respective Cramer class threshold?
The dietary exposure estimate to [FL-no: 16.127] is calculated to be 850 lg/person per day for
adults and 536 lg/person per day for children, corresponding to 14 lg/kg bw per day for a 60-kg
adult and 36 lg/kg bw per day for a 15-kg child. There is no known exposure from other sources.
The estimated dietary exposure for adults (850 lg/person per day) and for children (536 lg/person
per day) exceeds the threshold of concern for structure class III (90 lg/capita per day).
Step B4. Is the dietary exposure below 10 9 the respective Cramer class threshold?
The estimated dietary exposure for adults (850 lg/person per day) and for children (536 lg/person
per day) is below ten times the threshold for structural class III (i.e. 900 lg/person per day), and
according to the Procedure scheme, a 90-day toxicity study and a developmental toxicity study are
needed. For the substance [FL-no: 16.127], a NOAEL of 100 mg/kg bw per day (100,000 lg/kg bw
per day) from the 90-day oral toxicity study in rats could be identiﬁed. A developmental toxicity study
has been provided which shows that up to 1,000 mg/kg bw in rats (10-fold higher than the highest
exposure in the 90-day toxicity study) there is no indication of developmental toxicity.
The NOAEL of the 90-day oral toxicity study was considered in the risk assessment of the ﬂavouring
substance (see Section 2.10.1). The Procedure steps for the candidate substance are shown in
schematic form in Appendix A.
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2.12. Margin of safety (Table 5)
Based on the Procedure, the Panel concluded that there is no safety concern for the use of [FL-no:
16.127] as a ﬂavour modiﬁer at the estimated level of dietary exposure calculated using the APET
approach and based on the use levels in food as speciﬁed in Appendix C.
3. Conclusions
The ﬂavouring substance, 3-(1-((3,5-dimethylisoxazol-4-yl)methyl)-1H-pyrazol-4-yl)-1-(3-hydroxybenzyl)
imidazolidine-2,4-dione [FL-no: 16.127], contains a number of structural elements common to different
chemical groups listed in Annex I to Commission Regulation (EC) No 1565/20001 but cannot be
adequately covered by any existing FGE. Consequently, the Panel decided to assess this substance on
its own.
3-(1-((3,5-Dimethylisoxazol-4-yl)methyl)-1H-pyrazol-4-yl)-1-(3-hydroxybenzyl)imidazolidine-2,4-dione
has not been reported to occur in natural source materials of botanical or animal origin. There are no
reports of its detection in processed foods.
Speciﬁcations
Speciﬁcations including complete purity criteria and identity for the material of commerce have
been provided and considered adequate. The candidate substance does not possess chiral centres or
geometrical isomers.
The information provided on the manufacturing process, the composition and the stability of the
ﬂavouring substance was considered sufﬁcient.
Use and exposure
3-(1-((3,5-Dimethylisoxazol-4-yl)methyl)-1H-pyrazol-4-yl)-1-(3-hydroxybenzyl)imidazolidine-2,4-dione
is intended to be used as a modiﬁer2 of the bitter taste of speciﬁc food categories.
The cumulative dietary exposure to the candidate substance has been estimated using the APET. It
is calculated to be 850 lg/capita per day (14 lg/kg bw per day for a 60-kg adult) and 536 lg/capita
per day (36 lg/kg bw per day for a 15-kg 3-year-old child).
Although the substance is not intended to be used in food categories speciﬁcally intended for
infants and young children, these could still be exposed through consumption of foods from the
general food categories, which may contain the substance. However, at present, there is no generally
accepted methodology to estimate exposure in these age groups resulting from consumption of foods
from the general categories.
The highest acute intake of the candidate substance results from the consumption of non-alcoholic
beverages containing 8 mg/kg of the candidate substance consumed by a 15-kg 3-year-old child. This
results an intake of 4.5 mg/capita per day (or 300 lg/kg bw per day for a 15-kg 3-year-old child).
Absorption, distribution, metabolism and elimination
The ADME studies available for [FL-no: 16.127] indicate that the bioavailability of the compound is
2–4% of the orally administered dose. However, the information on the mass balance and metabolic
fate of the substance in vivo is incomplete. Therefore, the extent of absorption cannot be estimated
from the available data. In blood, mainly some conjugates and a minor amount of oxidised metabolites
were observed. In vitro studies with microsomes (rat and human) indicate very limited phase I
metabolism of the candidate substance.
Genotoxicity
No structural alerts have been identiﬁed for [FL-no: 16.127]. In tests carried out in vitro and
in vivo, [FL-no: 16.127] showed no potential to cause gene mutations, structural chromosomal
Table 5: Summary table on calculated margins of safety by toxicity studies
Study
NOAEL lg/kg bw
per day
Add APET lg/kg bw
per day
Margin of
safety
Adult 90-day dietary study in
rats (OECD 408)
100,000 14 > 7,000
Child 36 > 2,000
NOAEL: no-observed-adverse-effect-level; APET: added portions exposure technique; OECD: Organisation for Economic
Co-operation and Development.
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aberrations or numerical chromosomal aberrations. The Panel concluded that there is no cause for
concern with respect to genotoxicity.
Systemic toxicity
A 90-day systemic toxicity study in the rat has been performed. Dietary administration of [FL-no:
16.127] to CD rats for 13 weeks at doses up to 100 mg/kg bw per day was well tolerated, with the only
effect being a slight increase in motor activity which was observed only in the high-dose males. Based on
the ﬁndings in this study, the NOEL was considered to be 30 mg/kg bw per day for males and 100 mg/kg
bw per day for females, and the NOAEL was 100 mg/kg bw per day in both sexes.
Developmental toxicity
In a developmental toxicity study, rats were administered oral doses of 125–1,000 mg/kg bw per
day of the candidate substance. There were no differences between the treated and control groups.
Therefore, there is no concern for developmental toxicity of [FL-no: 16.127] in rats at dose levels up to
1,000 mg/kg bw per day.
Safety assessment for acute exposure
Estimates of maximum acute dietary exposure indicate that this would be about 0.3 mg/kg bw for
a 3-year-old child. Doses of 2,000 mg/kg bw and probably higher are well tolerated in mice without
adverse effects. No signiﬁcant changes in body weight or apparent signs of toxicity were observed in
mice administered this dose during the 48-h study period in an in vivo micronucleus assay. This results
in a margin of exposure of more than 6 9 103 for children and 1.7 9 104 for adults.
Safety assessment for long-term exposure
The safety of long-term exposure has been evaluated according to the Procedure for the evaluation
of chemically deﬁned ﬂavouring substances.
For the substance [FL-no: 16.127], there is no concern in relation to genotoxicity and it can be
evaluated through the Procedure.
There is no clear structural/metabolic similarity of the candidate substance to ﬂavouring substances
in an existing FGE and accordingly the candidate substance [FL-no: 16.127] has been individually
evaluated according to the EFSA Guidance document.
Based on its chemical structure, the substance has been assigned to Cramer class III. The results
of studies on metabolism and pharmacokinetics do not allow the conclusion that its metabolites are
innocuous. Accordingly, the candidate substance is evaluated via the B-side of the Procedure scheme.
Based on the comparison of APET with the Cramer class III threshold, a 90-day study and a
developmental toxicity study were required and carried out for this substance.
Overall, the Panel concluded that using the NOAEL obtained from a 90-day dietary study in rats, there
is no safety concern for [FL-no: 16.127], when used as a ﬂavour modiﬁer at the estimated level of dietary
exposure calculated using the APET approach and based on the use levels in food as speciﬁed in
Appendix C. An adequate margin of safety of over 7,000 for adults and 2,000 for 3-year-old children has
been estimated.
Documentation provided to EFSA
1) Flavour Industry, 2013. Unpublished information submitted by Flavour Industry to EFSA and
forwarded to FLAVIS Secretariat. A-400 [FL-no: 16.127].
2) Huntingdon Life Sciences, 2009a. S6893: Bacterial Reverse Mutation Screening Test
(5 strains).
3) Huntingdon Life Sciences, 2009b. S6821: Toxicity Study by Dietary Administration to CD Rats
for 4 Weeks.
4) Huntingdon Life Sciences, 2010a. S6821 Bacterial Reverse Mutation Test.
5) Huntingdon Life Sciences, 2010b. S6821: In Vitro Mammalian Chromosome Aberration Test
In Human Lymphocytes.
6) Huntingdon Life Sciences, 2010c. S6821: Mouse In Vivo Micronucleus Test.
7) Huntingdon Life Sciences, 2010d. S6821 Comparative In Vitro Metabolism Using Rat and
Human Liver Microsomes.
8) Huntingdon Life Sciences, 2010e. S6821: Toxicity Study by Dietary Administration to CD Rats
for 13 Weeks.
9) Huntingdon Life Sciences, 2011. S6821: Pharmacokinetic Study in Rats.
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10) Nucro-Technics, 2008a. TA98 And TA100 Reverse Mutation Test Of S6821.
11) Nucro-Technics, 2008b. Acute Oral Toxicity Study with S6821 in Rats.
12) Senomyx, 2010. In Vivo Metabolism of S6821 following a Single Oral Dose to Male Sprague-
Dawley Rats.
13) Senomyx, 2016. Responses to Request for Additional Information Application for
Authorisation of a Flavouring substance from FGE.400 submitted under Commission
Implementing Regulations (EC) No 872/2012, (EC) No 234/2011 and (EC) No 1334/2008 of
the European Parliament and Council EFSA-Q-2012-00871.
14) WIL Research 2015a. An Oral (Gavage) Dose Range-ﬁnding Developmental Toxicity Study
of S6821 in Rats. (WIL Study No. 884036).
15) WIL Research 2015b. An Oral (Gavage) Developmental Toxicity Study of S6821 in Rats.
(WIL Study No. 884037).
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ADME absorption, distribution, metabolism and elimination
APET added portions exposure technique
AUC area under the curve
bw body weight
CAS Chemical Abstract Service
CEF EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids
CoE Council of Europe
EC European Commission
FAO Food and Agriculture Organization of the United Nations
FDA US Food and Drug Administration
FEMA Flavor and Extract Manufacturers Association
FGE Flavouring Group Evaluation
FLAVIS (FL) Flavour Information System (database)
GC gas chromatography
GD gestation day
GLP good laboratory practice
GMO genetically modiﬁed organisms
GSFA General Standard for Food Additives
HPLC high-performance liquid chromatography
ID identity
IR infrared spectroscopy
JECFA The Joint FAO/WHO Expert Committee on Food Additives
LC liquid chromatography
LOD limit of detection
MS mass spectrometry
MSDI maximised survey-derived daily intake
NMR nuclear magnetic resonance
NOAEL no-observed-adverse-effect-level
NOEL no-observed-effect-level
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OECD Organisation for Economic Co-operation and Development
SD Sprague–Dawley
S9-MIX A metabolic activation system with rat liver microsome fraction plus cofactors
TTC threshold of toxicological concern
UHT ultrahigh temperature
UV ultraviolet
WHO World Health Organization
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Appendix A – Procedure scheme
Decision tree structural class
Data available to demonstrate that metabolites are to be considered innocuous?
Dietary exposure:
<1,800 μg/person per day (class I)
<540 μg/person per day (class II)
<90 μg/person per day (class III)
Dietary exposure:
Dietary exposure:
<18,000 μg/person per day (class I)
<5,400 μg/person per day (class II)
<900 μg/person per day (class III)
Dietary exposure:
• 90-day study
• Developmental toxicity
• Chronic toxicity carcinogenic study
• 90-day study
• Developmental toxicity
90-day study
No further data
Step 1.
Step 2.
Step A3.
Step A4.
Step B3.
Step B4.
Yes No
Yes
Yes
Yes
Yes
No
NoNo
No
< 1,800 μg/person per day (class I)
< 540 μg/person per day (class II)
< 90 μg/person per day (class III)
< 18,000 μg/person per day (class I)
< 5,400 μg/person per day (class II)
< 900 μg/person per day (class III)
Figure A.1: Individual evaluation of a ﬂavouring substance
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Appendix B – Structurally and metabolically related substances
No close structural analogues of the substance [FL-no: 16.127] were identiﬁed among the
ﬂavouring substances that have already been evaluated by EFSA.
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Appendix C – Use levels and exposure calculations
Table C.1: Normal and maximum occurrence levels for subcategories of foods and beverages
Food categories(a)
Standard
portions(b)
(g)
Occurrence level
as added
ﬂavouring
(mg/kg)
Occurrence level
from other
sources(e) (mg/kg)
Combined
occurrence level
all sources(d)
(mg/kg)
Normal Maximum Normal(c) Maximum Normal Maximum
01.1 Milk and dairy-based drinks 200 1 4 1 4
01.2 Fermented and renneted-milk products
(plain), excluding food category 01.1.2
(dairy-based drinks)
200 1 4 1 4
01.3 Condensed milk and analogues (plain) 70 2 8 2 8
01.4 Cream (plain) and the like 15 2 8 2 8
01.5 Milk powder and cream powder and
powder analogues (plain)
30 2 8 2 8
01.6 Cheese and analogues 40
01.7 Dairy-based desserts (e.g. pudding, fruit
or ﬂavoured yoghurt)
125 2 10 2 10
01.8 Whey and whey products, excluding
whey cheeses
200 1 4 1 4
02.1 Fats and oils essentially free from water 15
02.2 Fat emulsions mainly of type water-in-oil 15
02.3 Fat emulsions mainly of type water-in-oil,
including mixed and/or ﬂavoured
products based on fat emulsions
15
02.4 Fat-based desserts, excluding dairy-
based dessert products of category 1.7
50
03.0 Edible ices, including sherbet and sorbet 50 2 4 2 4
04.1.1 Fresh fruit 140
04.1.2 Processed fruit 125
04.1.2.5 Jams, jellies, marmalades 30
04.2.1 Fresh vegetables (including mushrooms
and fungi, roots and tubers, pulses and
legumes, and aloe vera), seaweed, and
nut and seed
200
04.2.2 Processed vegetables (including
mushrooms and fungi, roots and tubers,
pulses and legumes, and aloe vera),
seaweed, and nut and seed purees and
spreads (e.g. peanut butter) and nuts
and seeds
200
04.2.2.5 Vegetables (including mushrooms and
fungi, roots and tubers, pulses and
legumes, and aloe vera), seaweed, and
nut and seed purees and spreads (e.g.
peanut butter)
30
05.1 Cocoa products and chocolate products,
including imitations and chocolate
substitutes
40 6 15 6 15
05.1.3 Cocoa-based spreads, including ﬁllings 30
05.2 Confectionery, including hard and soft
candy, nougats, etc., other than 05.1,
05.3 and 05.4
30 8 16 8 16
05.3 Chewing gum 3 10 30 10 30
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Food categories(a)
Standard
portions(b)
(g)
Occurrence level
as added
ﬂavouring
(mg/kg)
Occurrence level
from other
sources(e) (mg/kg)
Combined
occurrence level
all sources(d)
(mg/kg)
Normal Maximum Normal(c) Maximum Normal Maximum
05.4 Decorations (e.g. for ﬁne bakery wares),
toppings (non-fruit) and sweet sauces
35
06.1 Whole, broken or ﬂaked grain, including
rice
200
06.2 Flours and starches (including soya bean
powder)
30
06.3 Breakfast cereals, including rolled oats 30 8 30 8 30
06.4 Pastas and noodles and like products
(e.g. rice paper, rice vermicelli, soya
bean pastas and noodles)
200
06.5 Cereal and starch-based desserts (e.g.
rice pudding, tapioca pudding)
200
06.6 Batters (e.g. for breading or batters for
ﬁsh or poultry)
30
06.7 Precooked or processed-rice products,
including rice cakes (Oriental type only)
200
06.8 Soya bean products (excluding soya
bean products of food category 12.9 and
fermented soya bean products of food
category 12.10)
100
07.1 Bread and ordinary bakery wares 50
07.2 Fine bakery wares (sweet, salty,
savoury) and mixes
80
08.1 Fresh meat, poultry and game 200
08.2 Processed meat, poultry and game
products in whole pieces or cuts
100
08.3 Processed comminute meat, poultry and
game products
100
08.4 Edible casings (e.g. sausage casings) 1
09.1.1 Fresh ﬁsh 200
09.1.2 Fresh molluscs, crustaceans and
echinoderms
200
09.2 Processed ﬁsh and ﬁsh products,
including molluscs, crustaceans and
echinoderms
100
09.3 Semipreserved ﬁsh and ﬁsh products,
including molluscs, crustaceans and
echinoderms
100
09.4 Fully preserved, including canned or
fermented, ﬁsh and ﬁsh products,
including molluscs, crustaceans and
echinoderms
100
10.1 Fresh eggs 100
10.2 Egg products 100
10.3 Preserved eggs, including alkaline, salted
and canned eggs
100
10.4 Egg-based desserts (e.g. custard) 125
11.1 Reﬁned and raw sugar 10
11.2 Brown sugar excluding products of food
category 11.1
10
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Food categories(a)
Standard
portions(b)
(g)
Occurrence level
as added
ﬂavouring
(mg/kg)
Occurrence level
from other
sources(e) (mg/kg)
Combined
occurrence level
all sources(d)
(mg/kg)
Normal Maximum Normal(c) Maximum Normal Maximum
11.3 Sugar solutions and syrups, and
(partially) inverted sugars, including
molasses and treacle, excluding products
of food category 11.1.3 (soft white
sugar, soft brown sugar, glucose syrup,
dried glucose syrup, raw cane sugar)
30
11.4 Other sugars and syrups (e.g. xylose,
maple syrup, sugar toppings)
30
11.5 Honey 15
11.6 Table-top sweeteners, including those
containing high-intensity sweeteners
1
12.1 Salt and salt substitutes 1 25 75 25 75
12.2 Herbs, spices, seasonings and
condiments (e.g. seasoning for instant
noodles)
1 25 100 25 100
12.3 Vinegars 15 12 25 12 25
12.4 Mustards 15 12 25 12 25
12.5 Soups and broths 200 1 4 1 4
12.6 Sauces and like products 30
12.7a Salads 120 g (e.g. macaroni salad,
potato salad) excluding cocoa- and
nut-based spreads of food categories
120
12.7b Sandwich spreads (20 g), excluding
cocoa- and nut-based spreads of food
categories
20
12.8 Yeast and like products 1
12.9 Soybean-based seasonings and
condiments
15
12.9.2 Soybean sauce 15
12.9.3 Fermented soybean sauce 15
12.9.1 Fermented soya bean products (e.g.
miso)
40 6 20 6 20
12.10 Protein products other than from
soybeans
15
13.2a Complementary foods for infants and
young children: dry instant cereals (with
or without milk), including pasta
110
13.2b Complementary foods for infants and
young children: meat-based or ﬁsh-
based dinner
170
13.2c Complementary foods for infants and
young children: dairy-based dessert
110
13.2d Complementary foods for infants and
young children: vegetables, potatoes,
broth, soups and pulses
170
13.2e Complementary foods for infants and
young children: biscuits and cookies
20
13.2f Complementary foods for infants and
young children: fruit puree
110
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Food categories(a)
Standard
portions(b)
(g)
Occurrence level
as added
ﬂavouring
(mg/kg)
Occurrence level
from other
sources(e) (mg/kg)
Combined
occurrence level
all sources(d)
(mg/kg)
Normal Maximum Normal(c) Maximum Normal Maximum
13.2g Complementary foods for infants and
young children: fruit juice
120
13.2h Milk for young children 200
13.3 Dietetic foods intended for special
medical purposes (excluding food
products of category 13.1 ‘Infant
formulae, follow-up formulae and other
formulae for special medical purposes for
infants’)
200 1 4 1 4
13.4(f) Dietetic formulae for slimming purposes
and weight reduction
200 1 4 1 4
13.5 Dietetic foods (e.g. supplementary foods
for dietary use), excluding products of
food categories 13.1 (Infant formulae,
follow-up formulae and other formulae
for special medical purposes for infants),
13.2–13.4 and 13.6
200 1 4 1 4
13.6 Food supplements 5 20 60 20 60
14.1 Non-alcoholic (‘soft’) beverages
(expressed as liquid)
300 2 8 2 8
14.2.1(f) Beer and malt beverages 300
14.2.2(f) Cider and perry 300
14.2.3(f) Grape wines 150
14.2.4(f) Wines (other than grape) 150
14.2.5(f) Mead 150
14.2.6(f) Distilled spirituous beverages containing
more than 15% alcohol
30
14.2.7(f) Aromatised-alcoholic beverages (e.g.
beer, wine and spirituous cooler-type
beverages, low-alcoholic refreshers)
300
15.1 Snacks, potato-, cereal-, ﬂour- or starch-
based (from roots and tubers, pulses
and legumes)
30 8 20 8 20
15.2 Processed nuts, including coated nuts
and nut mixtures (with e.g. dried fruit)
30
15.3 Snacks – ﬁsh based 30 8 20 8 20
16.0 Composite foods (e.g. casseroles, meat
pies, mincemeat) – foods that could not
be placed in categories 01–15
300
(a): Most of the categories reported are the subcategories of Codex GSFA (General Standard for Food Additives, available at http://www.
codexalimentarius.net/gsfaonline/CXS_192e.pdf) used by the JECFA in the SPET technique (FAO/WHO, 2008). In the case of category 13.2
(complementary foods for infants and young children), further reﬁned categories have been created so that a speciﬁc assessment of dietary
exposure can be performed in young children.
(b): In case of foods marketed as powder or as concentrates, occurrence levels must be reported for the reconstituted product, considering the
instructions reported on the product label or one of the standard dilution factors established by the JECFA (FAO/WHO 2008):
– 1/25 for powder used to prepare water-based drinks, such as coffee, containing no additional ingredients,
– 1/10 for powder used to prepare water-based drinks containing additional ingredients, such as sugars (ice tea, squashes, etc.),
– 1/7 for powder used to prepare milk, soups and puddings,
– 1/3 for condensed milk.
(c): In order to estimate normal values in each category, only foods and beverages in which the substance is present in signiﬁcant amount will be
considered (e.g. for the category ‘fresh fruit’ 04.1.1., the normal concentration will be the median concentration observed in all kinds of fruit where
the ﬂavouring substance is known to occur).
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Dietary exposure to [FL-no: 16.127] from the consumption of ﬂavoured foods and
beverages in adults and children
Chronic dietary exposure
Adults (‘added portions exposure technique’ (APET)).9
On the Basis of Normal Occurrence Level from Added Flavourings
Food subcategories resulting in the highest potential dietary exposure:
Beverage: The maximum intake will be from category 14.1 (non-alcoholic (‘soft’) beverages). The
normal combined occurrence level of 2 mg/kg gives an intake of 600 lg/person per day.
Solid Food: The maximum intake will be from category 1.7 (dairy-based desserts). The normal
combined occurrence level of 2 mg/kg gives an intake of 250 lg/person per day.
Total APET: 850 lg/person per day (14.2 lg/kg bw per day for a 60 kg person).
Children (3-year-old child of 15-kg body weight)
The adult portion sizes used in the APET calculations are adjusted by a factor 0.63 to compensate
for the lower portion sizes consumed by children.
Food subcategories resulting in the highest potential dietary exposure:
Beverage: The maximum intake will be from category 14.1 (non-alcoholic (‘soft’) beverages). The
normal combined occurrence level of 2 mg/kg gives an intake of 378 lg/child per day (2 mg/kg 9
0.63 9 300 g).
Solid Food: The maximum intake will be from category 01.7 (dairy-based desserts). The normal
combined occurrence of 2 mg/kg gives an intake of 158 lg/child per day (2 mg/kg 9 0.63 9 125 g).
Total APET10: 536 lg/child per day (35.7 lg/kg bw per day for a 15-kg child).
Conclusion
The total APET values are 14.2 lg/kg bw per day for 60-kg adults and 35.7 lg/kg bw per day for
15-kg children. In terms of per capita intake, the adult value of 850 lg/day is the higher.
Infants and young children
Although the substance is not intended to be used in food categories speciﬁcally intended for
infants and young children (food category 13.2a–13.2h), they could still be exposed through
consumption of foods from the general food categories, which may contain the substance. However,
for the moment, there is no generally accepted methodology to estimate exposure in these age groups
resulting from consumption of foods from the general categories.
Acute dietary exposure
Adults
The highest acute intake is assumed to result from the consumption of three portions11 of non-
alcoholic beverages (category 14.1) all containing a maximum concentration of 8 mg/kg of [FL-no:
16.127]. This gives a value of 3 9 300 g 9 8 mg/kg = 7.2 mg/capita = 0.12 mg/kg bw for a 60-kg
person.
(d): The normal and maximum combined occurrence levels of the substance will be assessed by the applicant either by adding up occurrence levels
from added use to that from other sources or by expert judgment based on the likelihood of their concomitant presence. This will be done both
for normal use levels and for maximum use levels.
(e): The data obtained will be an estimate of dietary exposure deriving from all dietary sources, excluding ﬂavourings added to foods and beverages.
(f): The subcategories 14.2.1, 14.2.2, 14.2.3 and 14.2.4 (‘alcoholic beverages’) and the subcategory 13.4 (‘dietetic formulae for slimming purposes and
weight reduction’) are a priori not consumed by children.
9 The APET has been calculated based on the occurrence levels in the food subcategories reported in the above Table, with the
exclusion of categories 13.2 (complementary foods for infants and young children).
10 Excluding subcategories 13.4, 14.2.1, 14.2.2, 14.2.3 and 14.2.4. Standard portion sizes for children are obtained by
multiplying the adult standard portion sizes by a factor of 0.63.
11 EFSA Journal 2010; 8(6):1623, Guidance on data submission for ﬂavourings evaluation: In both adults and 3-year-old children,
the acute exposure is represented by the consumption of three portions of either a solid food or a beverage, containing the
ﬂavouring substance at its maximum occurrence levels.
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Children12
The highest acute intake is assumed to result from the consumption of three portions
(3 9 300 9 0.63 = 567 g) of non-alcoholic beverages (category 14.1) all containing a maximum
concentration of 8 mg/kg of [FL-no: 16.127]. This gives an intake value of 567 g 9 8 mg/kg
= 4.5 mg/capita = 0.3 mg/kg bw for a 15-kg child.
Infants and young children
Although the substance is not intended to be used in food categories speciﬁcally intended for
infants and young children (food category 13.2a–13.2h), they will also consume food from the general
food categories, which may contain the substance. However, for the moment, there is no generally
accepted methodology to estimate exposure in these age groups resulting from consumption of foods
from the general categories.
Conclusion
The highest acute exposure13 is assumed to result from the consumption of three portions
(3 9 300 9 0.63 = 567 g) of non-alcoholic beverages (category 14.1) all containing a maximum
concentration of 8 mg/kg of [FL-no: 16.127]. This gives an intake value of 567 g 9 8 mg/kg
= 4.5 mg/capita = 0.3 mg/kg bw for a 15 kg 3-year-old child.
Cumulative Dietary Exposure to [FL-no: 16.127]
Any other ﬂavouring substances structurally and metabolically related to [FL-no: 16.127]: none
found.
Occurrence levels for structurally and metabolically related substances which have already been
evaluated in an FGE: none found.
Potential cumulative dietary exposure within 1 day to ﬂavouring substances structurally and
metabolically related to [FL-no: 16.127]: none found.
Potential non-food sources: none found.
Cumulative dietary exposure to [FL-no: 16.127] will therefore be 14.2 lg/kg bw per day for 60-kg
adults and 35.7 lg/kg bw per day for 15-kg infants. In terms of per capita intake, the adult value of
850 lg per day is the higher.
12 Based on the same considerations as for adults but using the special factors used for chronic exposure to infants.
13 The highest value obtained among adults and children of all ages.
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Appendix D – Absorption, distribution, metabolism and elimination
In vivo pharmacokinetics following a single-oral dose to rats
The objective of the study was to investigate the in vivo pharmacokinetics of [FL-no: 16.127]
following a single-oral administration to rat (Senomyx, 2010).
Male Sprague–Dawley (SD) rats were orally dosed with 100 mg/kg bw of [FL-no: 16.127] and blood
samples were collected at three time points (0.5, 2 and 4 h) after dosing (Senomyx, 2010). The
plasma samples were analysed by LC/MS/MS with an internal standard 3-(1-((3,5-dimethylisoxazol-4-
yl)methyl)-1H-pyrazol-4-yl)-1-(3-hydroxybenzyl)-5,5-dimethylimidazolidine-2,4-dione.
The maximum concentration of [FL-no: 16.127] in rat plasma was observed at the 0.5-h time point
in all the test animals (mean concentration: 105.4 ng/mL, n = 4). The mean concentrations of the
glucuronide of [FL-no: 16.127] (S7558) and the sulfate of [FL-no: 16.127] (S5907) in the plasma
samples during the 4-h sampling period were in the range of 32–166 ng/mL and 334–555 ng/mL,
respectively. The mean concentration of a monohydroxylated metabolite, 2,3-dihydroxybenzyl
derivative of [FL-no: 16.127] (S6887), was in the range of 12.6–18.9 ng/mL throughout the
observation period. Ions consistent with the presence of metabolites in which the isoxazole ring of
[FL-no: 16.127] has undergone oxidation were also seen in the extracted ion chromatograms. Sulfate
derivatives of the monohydroxylated metabolites were also observed. The samples were also analysed
for the presence of two alternative hydroxylated metabolites (S6260, S6262) and two potential
hydrolytic breakdown products (the hydantoin hydrolysis product of [FL-no: 16.127], referred to as
S6893; and the hydantoin ring-opened product of [FL-no: 16.127], referred to as S4687), but these
were either absent or below the limit of detection (< 1.0 ng/mL).
Conclusion
The primary metabolites of [FL-no: 16.127] in plasma are the glucuronide and sulfate conjugates of
unoxidised [FL-no: 16.127]. Minor amounts of monohydroxylation products [FL-no: 16.127] (on the
benzyl and isoxazole rings) as well as their corresponding sulfate conjugates were also observed.
Metabolite structures are shown in Figures D.1 and D.2.
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Figure D.1: Metabolically related substances, as indicated by the applicant
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Pharmacokinetic and metabolite detection study in rats following a single bolus
intravenous or oral dose
The objective of the study was to perform pharmacokinetic evaluation of both unchanged test
compound concentrations and concentrations of two of its conjugate metabolites (the sulfate S5907
and the glucuronide S7558), in plasma, following single-oral gavage or intravenous administration to
rats. (Huntingdon Life Sciences, 2011).
Four groups of six male SD rats were dosed; the ﬁrst by intravenous bolus administration at a
nominal dose of 1 mg/kg bw and the remaining three groups by oral gavage administration at nominal
dosages of 10, 30 and 100 mg/kg bw. Blood samples were collected post-dose, over nine time points
for the orally dosed groups and ten time points for the intravenously dosed group and centrifuged to
obtain plasma for pharmacokinetic analysis. Each group of animals was split into two subgroups of
three animals (cohorts) for the purposes of blood sampling. Sampling was alternated between cohorts
at each time point, such that only three animals were sampled at each time point. Samples were taken
at 0.25, 0.5, 1, 2, 4, 8, 12, 24 and 48 h post-dose with an additional time point at 5 min (0.083 h) for
the intravenously treated animals. Plasma samples were then analysed for the concentration of [FL-no:
16.127] and two of its conjugate metabolites (the sulfate S5907 and the glucuronide S7558) using a
suitable LC/MS/MS method.
Following intravenous administration of [FL-no: 16.127] to male SD rats, elimination of both the
parent substance [FL-no: 16.127] and its glucuronide S7758 was shown to be rapid with terminal half-
lives of 0.1 and 0.2 h, respectively. The terminal half-life of the sulfate S5907, however, was longer
than that of [FL-no: 16.127] indicating that the rate of formation of this metabolite was not the rate-
limiting step in its elimination. Systemic exposure, as reﬂected by the parameter ‘area under the curve’
(AUCall), was shown to be highest for metabolite S5907, whereas exposure to [FL-no: 16.127] and
metabolite S7558 were similar. The total plasma clearance of [FL-no: 16.127] was slightly lower than
the reported cardiac plasma output in rats and the volume of distribution at steady state was less than
the reported total body water in rats.
Following oral administration of [FL-no: 16.127] to male SD rats, [FL-no: 16.127] absorption was
rapid with a terminal half-life of [FL-no: 16.127] (at the highest dose level) of 4.3 h. The systemic
exposure of rats to [FL-no: 16.127] appeared to be characterised by non-linear kinetics. The Cmax
values increased by less than the proportionate dose interval, however, the AUCall values were up to
1.5-fold higher than the values predicted by a linear relationship. The systemic bioavailability of [FL-no:
16.127] following oral administration was low, with the rate and extent to which [FL-no: 16.127]
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Figure D.2: Proposed metabolic pathways of [FL-no: 16.127]
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reaches the systemic circulation (F) being only 2%, 4% and 2% following nominal oral doses of 10, 30
and 100 mg/kg bw, respectively. The terminal half-lives of metabolites S5907 and S7558 ranged
between 2.5–4.7 and 1.4–4.2 h, respectively, following oral doses of [FL-no: 16.127] between 10 and
100 mg/kg bw, with the longest half-lives being exhibited at the highest dosage. The Cmax and AUC
values for both metabolites increased with increasing dose over the range 10–100 mg/kg bw [FL-no:
16.127], however, the increases were less than the proportionate dose increment.
Conclusion
The systemic bioavailability of [FL-no: 16.127] following oral administration was low, with
percentage values for F of 2%, 4% and 2% following nominal oral doses of 10, 30 and 100 mg/kg bw,
respectively, suggesting that systemic exposure may be absorption limited. Following intravenous
administration of [FL-no: 16.127] to male SD rats, elimination of both the parent and its glucuronide
conjugate (S7758) were shown to be rapid with terminal half-lives of 0.1 and 0.2 h, respectively. The
terminal half-life of the sulfate conjugate S5907, however, was longer than that of [FL-no: 16.127],
although still rapid being 2.9, 2.5 and 4.7 h, respectively, at these doses. Following oral administration
of [FL-no: 16.127] to male rats, [FL-no: 16.127] absorption was rapid with a terminal half-life of 4.3 h
(at the highest dose level). The terminal half-lives of metabolites S5907 and S7558 ranged between
2.5–4.7 and 1.4–4.2 h, respectively. Systemic exposure to the parent and metabolites, was shown to
increase with increasing dosage, however, the increases in Cmax were lower than predicted from a
linear relationship. Therefore, exposure to [FL-no: 16.127] or its major metabolites was minimal.
However, the limited absorption and limited metabolism have not been conﬁrmed by, e.g. experiments
in a metabolism cage in which after oral administration, it is shown that over 95% of the dose is
excreted unchanged in faeces.
In vitro biotransformation in rat and human liver microsomes
The objective of this study was to investigate and compare the Phase I metabolism of [FL-no:
16.127] using liver microsomes from rat and human (Huntingdon Life Sciences, 2010d).
The Phase I metabolism of [FL-no: 16.127] was investigated using liver microsomes from rat and
human. [FL-no: 16.127] (1, 10 and 50 µM) was incubated with pooled-rat and pooled-human liver
microsomes (0.5 mg/mL) for up to 120 min. The reaction was stopped by addition of acetonitrile. The
samples were centrifuged and the supernatants taken for LC/MS analysis. LC/MS analysis of rat and
human liver microsomes incubation samples was carried out on a Waters Symmetry C18 column
(150 x 3.9 mm) with 0.1% formic acid and acetonitrile gradient system. The TSQ7000 mass
spectrometer was operated in positive ionisation mode.
LC/MS results indicate that rat liver microsomes formed primarily one monohydroxylated metabolite
of [FL-no: 16.127] identiﬁed as 3,4-dihydroxybenzyl-[FL-no: 16.127] (S6260). Human liver microsomes
formed at least four identiﬁable monohydroxylated metabolites. Two are hydroxylated on the benzyl
ring, 2,5-dihydroxybenzyl-[FL-no: 16.127] (S6262) and 3,4-dihydroxybenzyl-[FL-no: 16.127] (S6260).
The structures were conﬁrmed by LC/MS comparison to authentic compounds. The other two were
monohydroxylated at undetermined positions on the dimethylisoxazole ring as conﬁrmed by product
ion mass spectra.
Overall conclusions on absorption, distribution, metabolism and elimination
The ADME studies available for [FL-no: 16.127] indicate that the bioavailability of the compound is
2–4% of the orally administered dose. However, the information on the mass balance and metabolic
fate of the substance in vivo is incomplete; therefore the extent of absorption cannot be estimated
from the available data. The studies reported in this Appendix indicate that the primary metabolites of
[FL-no: 16.127] in plasma are the glucuronide and sulfate conjugates of [FL-no: 16.127]. Only very
small amounts of monohydroxylation products (of the benzyl and isoxazole rings) as well as their
corresponding sulfate conjugates were also observed. The study in rat liver microsomes indicated the
formation of one monohydroxylated metabolite of [FL-no: 16.127] identiﬁed as 3,4-dihydroxybenzyl-
[FL-no: 16.127] (identiﬁed as S6260 in Figure D.1 in Appendix D). Human liver microsomes formed at
least four detectable monohydroxylated metabolites. Two are hydroxylated on the benzyl ring: the 2,5-
dihydroxybenzyl derivative of [FL-no: 16.127] and the 3,4-dihydroxybenzyl derivative of [FL-no:
16.127] (identiﬁed, respectively, as S6262 and S6260 in Figure D.1 in Appendix D).
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Appendix E – Genotoxicity
Genotoxicity data in vitro
Bacterial Reverse Mutation Assay
The candidate substance was tested in Salmonella Typhimurium strains TA98, TA100, TA1535 and
TA1537, and Escherichia coli strain WP2 uvrA in accordance with the OECD Guideline 471 (Huntingdon
Life Sciences, 2010a). Two independent mutation tests were performed in the presence and absence
of liver preparations (S9-mix) from rats treated with phenobarbital and 5,6-benzoﬂavone. The ﬁrst test
was a standard plate incorporation assay; the second included a preincubation stage.
Concentrations of [FL-no: 16.127] up to 5,000 lg/plate were tested. Other concentrations used
were a series of ca. half-log10 dilutions of the highest concentration.
No signs of toxicity were observed towards the tester strains in either mutation test following
exposure to [FL-no: 16.127]. No evidence of mutagenic activity was seen at any concentration of
[FL-no: 16.127] in either mutation test. The concurrent positive controls demonstrated the sensitivity
of the assay and the metabolising activity of the liver preparations.
It was concluded that the candidate substance was not mutagenic to S. Typhimurium strains TA98,
TA100, TA1535 and TA1537, and E. coli strain WP2 uvrA, when tested in accordance with regulatory
guidelines.
A bacterial reverse mutation test was also conducted on the amine hydrolysis product (S6893 – see
Figure 1; Huntingdon Life Sciences, 2009a). The amine hydrolysis product, S6893 (is the same as
DP192), tested in S. Typhimurium strains TA98, TA100, TA1535 and TA1537, and E. coli strain WP2
uvrA in the absence and presence of metabolic activation (plate incorporation assay only), did not
induce gene mutations.
It was concluded that S6893 was not mutagenic in this bacterial system under the test conditions
employed.
Chromosome Aberration Test
An in vitro chromosome aberration test was performed on [FL-no: 16.127] in order to investigate
its potential to induce structural chromosome aberrations in cultured-human lymphocytes. The
experimental design followed the OECD Guideline 473 (Huntingdon Life Sciences, 2010b).
First test: In the absence and presence of S9-mix – 3 h treatment, 18 h recovery. Concentrations
tested: 296.6, 494.3 and 823.8 lg/mL. In the absence of S9-mix, appropriate toxicity was achieved at
the two highest concentrations (relative mitotic index: 66%). However, in the presence of S9-mix, no
signiﬁcant reduction in the mitotic index was achieved, even at the highest concentration.
Second test: In the absence of S9-mix – 21 h continuous treatment. Concentrations tested: 200,
400 and 600 lg/mL. In the presence of S9-mix (5% v/v) – 3 h treatment, 18 h recovery.
Concentrations tested: 1,100, 1,200 and 1,300 lg/mL. Both in the absence and in the presence of
S9-mix appropriate toxicity was achieved (relative mitotic index: 70% and 51% at 400 and 600 lg/mL
in the absence of S9-mix, respectively; 67% and 51% at 1,200 and 1,300 lg/mL in the presence of
S9-mix, respectively).
In the absence of S9-mix, [FL-no: 16.127] caused no statistically signiﬁcant increases in the
proportion of metaphase ﬁgures containing chromosomal aberrations, at any concentration, when
compared with the solvent control, in either test. In the ﬁrst test in the presence of S9-mix, no
statistically signiﬁcant increases in the proportion of metaphase ﬁgures containing chromosomal
aberrations were observed at any concentration. However, no signiﬁcant reduction in the mitotic index
was achieved at the used concentrations; therefore, the results of this test have to be considered as
inconclusive. In the second test in the presence of S9-mix, appropriate reduction in the mitotic index
was achieved at concentrations higher than those used in the ﬁrst test. Under the experimental
conditions used in the second test in the presence of S9-mix, no statistically signiﬁcant increases of
chromosomal aberrations were observed at any concentration.
No statistically signiﬁcant increases in the proportion of polyploid cells were observed during
metaphase analysis, in either test.
All positive control compounds caused statistically signiﬁcant increases in the proportion of aberrant
cells, demonstrating the sensitivity of the test system and the efﬁcacy of the S9-mix.
It is concluded that [FL-no: 16.127] shows no evidence of causing an increase in the frequency of
structural chromosome aberrations in this in vitro cytogenetic test system, under the experimental
conditions described.
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Genotoxicity data in vivo
Mouse Micronucleus Test
A mouse micronucleus test was performed with [FL-no: 16.127] in accordance with the OECD
Guideline 474 (Huntingdon Life Sciences, 2010c).
The preliminary toxicity test demonstrated that a dose of 2,000 mg/kg bw per day, administered on
two consecutive occasions approximately 24 h apart, was tolerated. On the basis of these results, dose
levels of 500, 1,000 and 2,000 mg/kg bw per day were selected for the micronucleus test. No substantial
differences in toxicity were observed between the sexes; therefore, the main test was performed using
male animals only. The vehicle was 1% methylcellulose in puriﬁed water. All animals in the vehicle control
and test substance dose groups were dosed orally by gavage using a dose volume of 10 mL/kg. The
positive control group animals were dosed orally by gavage using a dose volume of 20 mL/kg. The
negative control group received the vehicle 1% methylcellulose in puriﬁed water and the positive control
group received Mitomycin C at 12 mg/kg bw. Bone marrow smears were obtained from animals in the
vehicle control and in each of the test substance groups 24 h after administration of the second dose. In
addition, bone marrow smears were also obtained from animals in the positive control group 24 h after a
single dose. One smear from each animal was examined for the presence of micronuclei in 2,000
polychromatic erythrocytes. The proportion of polychromatic erythrocytes was assessed by examination
of at least 1,000 erythrocytes from each animal. A record of the incidence of micronucleated
normochromatic erythrocytes was also kept.
No statistically signiﬁcant increases in the frequency of micronucleated polychromatic erythrocytes
and no statistically signiﬁcant decreases in the proportion of polychromatic erythrocytes were observed
in CD1 mice treated with [FL-no: 16.127] at any treatment level, compared to vehicle control values.
The positive control compound, Mitomycin C, produced a statistically signiﬁcant increase in the
frequency of micronucleated polychromatic erythrocytes (p < 0.01).
The mean concentrations of [FL-no: 16.127] in test formulations analysed during the study were
within the applied limits (100  10%), conﬁrming the accuracy of the formulation(s).
It is concluded that [FL-no: 16.127] did not show any evidence of causing an increase in the
induction of micronucleated polychromatic erythrocytes or bone marrow cell toxicity in male CD1 mice
when administered orally by gavage in this in vivo test procedure. The test material was not
clastogenic and it did not interact with the mitotic spindle.
The Panel noted that bone marrow exposure was not demonstrated in the in vivo micronucleus
assay. However, as the in vitro chromosomal aberration assay was negative, there is no need for
further in vivo follow-up.
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Appendix F – Toxicity
Acute oral toxicity study in rats
This preliminary test was carried out on [FL-no: 16.127] in order to ensure that there are no likely
acute toxic effects that would preclude the initial sensory examination of this material at low levels as
a ﬂavouring agent (Nucro-Technics, 2008b). Three groups of ﬁve female SD rats were tested. Group 1,
Group 2 and Group 3 animals were administered dose levels of 5, 15 and 50 mg/kg bw, respectively,
at dose concentrations of 0.5, 1.5 and 5.0 mg/mL. The test article was suspended in 1% methyl
cellulose and was administered by oral gavage at a dose volume of 10 mL/kg. The animals were
observed for an 8-day period after dosing. Body weights were recorded prior to test article
administration (day 0), on day 4, day 7 and prior to necropsy on day 8.
No mortality or evidence of toxicity were observed post-dosing or during the 8-day observation
period in any of the animals. Animals in each group gained body weight by the end of study. Based on
clinical observations and gross necropsy, the test article, [FL-no: 16.127], did not show any evidence
of toxicity when administered orally to rats at dose levels of up to 50 mg/kg bw under the
aforementioned testing conditions.
28-day rat range-ﬁnding dietary toxicity study in rats
A range-ﬁnding oral toxicity screening study was carried out in rats on [FL-no: 16.127] in order to
provide information for dose selection of the subsequent 90-day toxicity study in rats (Huntingdon Life
Sciences, 2009b).
The potential systemic toxicity of [FL-no: 16.127] was evaluated in male and female Crl:CD®(SD)
rats (5/sex per group). The study was conducted in compliance with the US FDA Toxicological
Principles for the Safety of Food Ingredients (as revised in 2004). The compound was administered in
the diet at doses of 0 (control), 10, 30 or 100 mg/kg bw per day for a period of 28 days. Survival,
clinical observation, body weight, food consumption, haematology, clinical chemistry, organ weights
and macroscopic evaluations of all animals were used to assess potential toxicity. The livers and gross
lesions of all animals were subjected to histopathological examination.
The compound induced no treatment-related changes in mortality, clinical observations, body
weights, food consumption, haematology or clinical chemistry parameters. Macroscopic examination at
necropsy, organ weights and microscopic examination of the liver were unremarkable.
Therefore, dietary administration of [FL-no: 16.127] to CD rats for 4 weeks at doses up to 100 mg/kg bw
per day was well tolerated, as there was no evidence of toxicity.
90-day dietary toxicity study in rats
[FL-no: 16.127] (99% pure) was administered in the diet of rats over 90 days in order to evaluate
its subchronic toxicity (Huntingdon Life Sciences, 2010e). This study was designed to be in accordance
with the OECD Guideline 408 and the guidelines of the US FDA Red Book and was conducted in
accordance with the requirements of current, internationally recognised GLP standards.
The potential systemic toxicity of [FL-no: 16.127] was evaluated in male and female Crl:CD(SD) rats
(20/sex/group). The compound was administered in the diet at doses of 0 (control), 10, 30, or
100 mg/kg bw per day for a period of 13 weeks. Survival, clinical observation, body weight, food
consumption, ophthalmic and physical examinations, haematology, clinical chemistry, urinalysis, motor
activity, sensory reactivity and grip strength, organ weights, and macroscopic and microscopic
evaluations were determined.
There were no treatment-related changes in mortality, clinical observations, sensory reactivity and
grip strength, body weights, food consumption, ophthalmic exams, haematology, clinical chemistry or
urinalysis parameters. Macroscopic examination at necropsy, organ weights and microscopic
examinations were unremarkable. Motor activity scores (both high and low beam) were slightly
increased, when compared to the controls, for males receiving 100 mg/kg bw per day. Males and
females receiving 10 and 30 mg/kg bw per day and females receiving 100 mg/kg bw per day were not
affected. As there were no other changes that were indicative of toxicity in these animals, the increase
in motor activity was not considered adverse.
In conclusion, dietary administration of [FL-no: 16.127] to CD rats for 13 weeks at doses up to
100 mg/kg bw per day was well tolerated, with the only effect being a slight increase in motor activity
which was observed only in the high-dose males. Based on the ﬁndings in this study, the NOEL was
considered to be 30 mg/kg bw per day for males and 100 mg/kg bw per day for females, and the
NOAEL was 100 mg/kg bw per day in both sexes.
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Developmental toxicity study in rats
A non-GLP compliant range-ﬁnding study (WIL Research, 2015a) was performed in groups of 8 female
rats (Crl:CD(SD)), who were administered 125, 250, 500 and 1,000 mg 3-(1-((3,5-dimethylisoxazol-4-yl)
methyl)-1H-pyrazol-4-yl)-1-(3-hydroxybenzyl)-imidazolidine-2,4-dione [FL-no: 16.127]/kg bw per day,
suspended in 1% methylcellulose. The control group received vehicle only. Administration was once daily
by oral gavage at 10 mL/kg bw from gestation day (GD) 6–20. Mortality, signs of external clinical changes,
body weight and food consumption were monitored. On GD 21, laparohysterectomy was performed.
Dosages were analytically conﬁrmed. No maternal mortality or abortions were observed. No
incidences of external clinical manifestations or changes in body weight, gravid uterine weight or food
consumption were observed. There were also no signiﬁcant differences in sex ratio, numbers of viable
fetuses (no dead fetuses observed), early- or post-implantation losses, number of implantation sites,
number of corpora lutea, preimplantation embryo loss or mean fetal weights. There was only one
single incidence of an abnormal fetus at 250 mg/kg bw per day.
The study conclusion to use doses of 125, 500 and 1,000 mg/kg bw per day for the full
developmental toxicity study is justiﬁed.
The full developmental toxicity study was conducted according to GLP and followed OECD Test No
414: Prenatal Development Toxicity Study Guidelines (WIL Research, 2015b). Groups of 25 female rats
(Crl:CD(SD) ~ 14 weeks old) were administered 125, 500 and 1,000 mg test compound [FL-no:
16.127]/kg bw per day, suspended in 1% methylcellulose. The control group received vehicle only.
Administration was once daily by oral gavage at 10 mL/kg bw from GD 6–20. Twice daily mortality and
moribundity were checked, and signs of external clinical changes, body weight and food consumption
were monitored. On GD 21, laparohysterectomy was performed, followed by extensive examination of
the relevant organs in the dams and the fetuses as indicated in OECD test 414, similar but more
extensive than in the range-ﬁnding study.
No incidences of maternal mortality, abortion or requirement for killing were reported; two controls
and three of the 1,000 mg/kg bw per day females were non-gravid. No signiﬁcant differences in
clinical observations of the dams were reported, including hair loss, dosage reaction, body weight
changes, gravid uterus weights or food consumption. At GD 21, there were no signiﬁcant differences
reported for: number of viable fetuses, dead fetuses (zero for all groups), early/late resorptions, post-
implantation embryo loss, number of implantation sites and corporal lutea, preimplantation embryo
loss, twining rate or sex ratio. Only the body weights of female fetuses in the 125 mg/kg bw per day
group were signiﬁcantly (5.7%) heavier than controls. There were no differences in the incidences of
fetal malformations between all groups.
Conclusion
In a developmental toxicity study, according to GLP and OECD test guideline 414, rats were
administered oral doses of 125–1,000 mg/kg bw per day of the candidate substance. There were no
differences between the treated and control groups. Therefore, there is no concern for developmental
toxicity of [FL-no: 16.127] in rats at dose levels up to 1,000 mg/kg bw per day.
Table F.1: Genotoxicity data (in vitro)
Chemical name
[FL-no]
Test system Test object Concentration
Reported
result
Reference Comments
(3-(1-((3,5-
Dimethylisoxazol-4-yl)
methyl)-1H-pyrazol-4-
yl)-1-(3-hydroxybenzyl)
imidazolidine-2,4-
dione) [16.127]
Ames test Salmonella
Typhimurium TA98
and TA100
Up to 5
mg/plate(a)
Negative Nucro-Technics
(2008a)
Initial screening
test
Ames test Salmonella
Typhimurium TA98,
TA100, TA1535 and
TA1537
Escherichia coli
WP2 uvrA
Up to 5
mg/plate(a)
Negative Huntingdon Life
Sciences (2010a)
Test in according
with OECD
Guideline 471.
GLP
Chromosome
aberration
test
Human
lymphocytes
Up to 823.8
lg/mL(b)
and 1,300
lg/mL(c)
Negative Huntingdon Life
Sciences
(2010b)
Test in
accordance with
OECD Guideline
473. GLP
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Table F.2: Genotoxicity data (in vivo)
Chemical
name
[FL-no]
Test system
Test
object
Route Dose
Reported
result
Reference Comments
[16.127] Micronucleus
test
Mice Oral by
gavage
Up to 2,000
mg/kg bw
Negative Huntingdon Life
Sciences (2010c)
Test in accordance
with OECD Guideline
474. GLP
GLP: good laboratory practice; OECD: Organisation for Economic Co-operation and Development.
Chemical name
[FL-no]
Test system Test object Concentration
Reported
result
Reference Comments
Hydrolysis product;
S6893
Ames test Salmonella
Typhimurium TA98,
TA100, TA1535 and
TA1537
E. coli WP2 uvrA
Up to 5,000
lg/plate(a)
Negative Huntingdon Life
Sciences (2009a)
GLP: good laboratory practice; OECD: Organisation for Economic Co-operation and Development.
(a): With and without metabolic activation.
(b): Without metabolic activation.
(c): With metabolic activation.
Table F.3: Toxicity data (in vivo)
Chemical name
[FL-no]
Species; sex
no/group
Route
Doses (mg/kg
bw per day)
Duration
Result (mg/kg bw
per day)
Reference Comments
(3-(1-((3,5-
Dimethylisoxazol-
4-yl)methyl)-1H-
pyrazol-4-yl)-1-
(3-hydroxybenzyl)
imidazolidine-2,
4-dione) [16.127]
Sprague–Dawley
rats; 5 female/
dose level
Gavage 0, 5, 15 and
50 mg/kg bw
Single dose,
8 days
observation
– Nucro-
Technics
(2008b)
Pretesting
screening test
Mouse Gavage 2,000 mg/kg bw Single dose,
8 days
– Huntingdon
Life Sciences
(2010c)
Range-ﬁnding
study for mouse
micronucleus
shows that a
single dose of
2,000 mg/kg bw
is well tolerated
Crl:CD(SD) rats:
5 male, 5 female
per dose level
Dietary 0, 10, 30 or
100 mg/kg bw
per day
28-days – Huntingdon
Life Sciences
(2009b)
Range-ﬁnding
study
Crl:CD(SD) rats:
10 male, 10
female per dose
level
Dietary 0, 10, 30 or
100 mg/kg bw
per day
13 weeks
(91 days)
NOEL: 30 mg/kg bw
per day
NOAEL: 100 mg/kg bw
per day
Huntingdon
Life Sciences
(2010e)
Test in
accordance with
OECD Test
Guideline 408.
GLP
GLP: good laboratory practice; NOAEL: no-observed-adverse-effect-level; NOEL: no-observed-effect-level; OECD: Organisation for Economic Co-operation
and Development.
Table F.4: Developmental toxicity data (in vivo)
Chemical
name
[FL-no]
Species; sex
no/group
Route
Doses
(mg/kg bw
per day)
Duration
Result (mg/kg
bw per day)
Reference Comments
[16.127] Crl:CD(SD) rats:
25 pregnant
female/dose
level
Oral
gavage
0, 125, 500,
1,000 mg/kg bw
per day
Gestational;
days 6–20
NOAEL:
1,000 mg/kg bw
per day
WIL Research
(2015b)
Developmental toxicity
study. Conducted in
accordance to OECD
Guideline 414. GLP
GLP: good laboratory practice; NOAEL: no-observed-adverse-effect-level; OECD: Organisation for Economic Co-operation and Development.
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Appendix G – Summary of the procedure
Table G.1: Summary of the procedure for the evaluation of individual ﬂavouring substances
FL-no
JECFA no
CAS no
Union list
name
Structural
formula
Procedure
pathway
(A or B)(a)
Class(b)
Evaluation
procedure
path(a)
Toxicological
data required
Chronic APET
µg/person per
day (adult or
child)(c)
EFSA
conclusion
16.127
2161
1119831-25-2
(3-(1-((3,5-
Dimethylisoxazol-
4-yl)methyl)-1H-
pyrazol-4-yl)-1-
(3-hydroxybenzyl)
imidazolidine-2,
4-dione)
HO
N N
N
N
N
O
O
O
B Class III
B3: Intake
10 times
below
TTC
90-day study
Developmental
toxicity study
850 Studies are
available and
the margin of
safety can be
calculated
APET: added portions exposure technique; CAS: Chemical Abstract Service; JECFA: The Joint FAO/WHO Expert Committee on Food Additives.
(a): Are data available to demonstrate that metabolites are to be considered innocuous? Yes: A; No: B.
(b): Thresholds of concern: Class I = 1,800 µg/person per day, Class II = 540 µg/person per day, Class III = 90 µg/person per day.
(c): The highest chronic APET value among adults and children expressed in µg/person per day.
Table G.2: Summary of the evaluation of metabolites
FL-no
JECFA no
Union list
name/code
name
Estimated
amount MSDI
(EU) µg/capita
per day
EFSA status
Cramer
class
Comments
Non-Register S7558(a) Glucuronide
conjugate of
[FL-no: 16.127](a)
Not available Not evaluated
as a ﬂavour
III Conjugate of
candidate
substance
Non-Register S5907(a) Sulfate conjugate of
[FL-no: 16.127](a)
Not available Not evaluated
as a ﬂavour
III Conjugate of
candidate
substance
Non-Register S6887(a) 2,3-dihydroxybenzyl
derivative of [FL-no:
16.127](a)
Not available Not evaluated
as a ﬂavour
III Hydroxylated
metabolite
JECFA: The Joint FAO/WHO Expert Committee on Food Additives; MSDI: maximised survey-derived daily intake.
(a): See Figure D.1.
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